Previous work from our group has shown that anti-TNF therapy reduces NFkB and IFN inflammatory signatures, restores skewed M1:M2 macrophage differentiation, reduces perivascular TNF and restores endothelial integrity in individuals with vascular manifestations of DADA2 (3). The gene discussed is TNF; the disease is deficiency of adenosine deaminase 2.